View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2012	Oct. 25, 2012
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Trading Symbol	NBIX
Entity Registrant Name	NEUROCRINE BIOSCIENCES INC
Entity Central Index Key	0000914475
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		66,384,690

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 44,488	$ 50,107
Short-term investments, available for sale	129,473	78,996
Receivables under collaboration agreements	1,369	1,903
Other current assets	2,688	1,470
Total current assets	178,018	132,476
Property and equipment, net	2,034	1,586
Long-term investments	8,865
Restricted cash	4,334	4,306
Total assets	193,251	138,368
Current liabilities:
Accounts payable	1,416	1,111
Accrued liabilities	8,130	8,451
Current portion of deferred revenues	10,177	34,242
Current portion of cease-use liability	280	264
Current portion of deferred gain on sale of real estate	3,110	3,042
Total current liabilities	23,113	47,110
Deferred revenues	728	2,919
Deferred gain on sale of real estate	21,661	24,005
Deferred rent	2,023	1,800
Cease-use liability	2,269	2,328
Other liabilities	152	125
Total liabilities	49,946	78,287
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 110,000,000 shares authorized; issued and outstanding shares were 66,381,135 as of September 30, 2012 and 55,262,734 as of December 31, 2011	66	55
Additional paid-in capital	872,383	784,811
Accumulated other comprehensive income (loss)	19	(87)
Accumulated deficit	(729,163)	(724,698)
Total stockholders' equity	143,305	60,081
Total liabilities and stockholders' equity	$ 193,251	$ 138,368

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2012	Dec. 31, 2011
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	110,000,000	110,000,000
Common stock, shares issued	66,381,135	55,262,734
Common stock, shares outstanding	66,381,135	55,262,734

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenues:
Sponsored research and development	$ 1,369	$ 2,396	$ 4,938	$ 8,589
Milestones and license fees	7,988	39,238	26,255	57,714
Total revenues	9,357	41,634	31,193	66,303
Operating expenses:
Research and development	9,860	7,456	28,066	22,949
General and administrative	3,324	3,825	10,126	9,790
Cease-use expense	135	(87)	135	89
Total operating expenses	13,319	11,194	38,327	32,828
(Loss) income from operations	(3,962)	30,440	(7,134)	33,475
Other income:
Gain on sale/disposal of assets		86	25	184
Deferred gain on real estate	759	736	2,276	2,209
Investment income, net	123	102	359	341
Other income, net	2	18	9	31
Total other income	884	942	2,669	2,765
Net (loss) income	$ (3,078)	$ 31,382	$ (4,465)	$ 36,240
Net (loss) income per common share:
Basic	$ (0.05)	$ 0.57	$ (0.07)	$ 0.66
Diluted	$ (0.05)	$ 0.56	$ (0.07)	$ 0.64
Shares used in the calculation of net (loss) income per common share:
Basic	66,342	55,248	65,355	55,148
Diluted	66,342	56,378	65,355	56,309
Other comprehensive (loss) income:
Net (loss) income	$ (3,078)	$ 31,382	$ (4,465)	$ 36,240
Net unrealized gains (losses) on available-for-sale securities	162	(140)	106	(111)
Comprehensive (loss) income	$ (2,916)	$ 31,242	$ (4,359)	$ 36,129

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$ (4,465)	$ 36,240
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	481	552
Gain on sale of assets	(2,301)	(2,393)
Cease-use expense	135	89
Deferred revenues	(26,256)	(27,788)
Deferred rent	238	332
Amortization of premiums on investments	2,480	1,772
Non-cash share-based compensation expense	4,169	2,011
Change in operating assets and liabilities:
Receivables under collaboration agreements and other assets	(684)	(18,309)
Accounts payable and accrued liabilities	(16)	(1,085)
Cease-use liability	(193)	(3,162)
Other liabilities	27	23
Net cash used in operating activities	(26,385)	(11,718)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments	(139,505)	(104,186)
Sales and maturities of investments	77,789	101,654
Deposits and restricted cash	(28)	(26)
Proceeds from sales of property and equipment	25	187
Purchases of property and equipment	(929)	(710)
Net cash used in investing activities	(62,648)	(3,081)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock	83,414	264
Net cash provided by financing activities	83,414	264
Net decrease in cash and cash equivalents	(5,619)	(14,535)
Cash and cash equivalents at beginning of the period	50,107	54,051
Cash and cash equivalents at end of the period	$ 44,488	$ 39,516

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2012

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Description of Business. Neurocrine Biosciences, Inc. (the Company or Neurocrine) was incorporated in California in 1992 and reincorporated in Delaware in 1996. The Company discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. The Company’s product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. While the Company independently develops many of its product candidates, it has entered into collaborations for several of its programs. The Company’s lead clinical development program, elagolix, is a drug candidate for the treatment of endometriosis and uterine fibroids that is partnered with Abbott International Luxembourg S.à r.l. (Abbott).

Basis of Presentation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary.

These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2011 included in the Company’s Annual Report on Form 10-K filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2011 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

Impact of Recently Issued Accounting Standards. In December 2011, the Financial Accounting Standards Board (FASB) issued accounting guidance requiring an entity to disclose information about offsetting arrangements and the impact of these arrangements on the Company’s financial position. This guidance is effective for interim and annual periods beginning on or after January 1, 2013. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.

In May 2011, the FASB issued updated accounting guidance that clarifies existing fair value measurements and disclosures, and eliminates differences between GAAP and International Financial Reporting Standards to make convergence guidance more understandable. This guidance is effective for interim and annual periods beginning after December 15, 2011. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements.

Effective January 1, 2012, the Company adopted guidance issued by the FASB concerning presentation and disclosure only for the presentation of comprehensive (loss) income. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial position or results of operations, other than its impact on the presentation of comprehensive (loss) income.

Use of Estimates. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS

9 Months Ended

Sep. 30, 2012

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS

2. REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS

Revenue Recognition Policy. Revenues under collaborative agreements and grants are recognized as research costs are incurred over the period specified in the related agreement or as the services are performed. These agreements are on a best-efforts basis, do not require scientific achievement as a performance obligation and provide for payment to be made when costs are incurred or the services are performed. All fees are nonrefundable to the collaborators. Prior to the revised multiple element guidance adopted by the Company on January 1, 2011, upfront, nonrefundable payments for license fees, grants, and advance payments for sponsored research revenues received in excess of amounts earned were classified as deferred revenue and recognized as income over the contract or development period. Estimating the duration of the development period includes continual assessment of development stages and regulatory requirements. If and when the Company enters into a new collaboration agreement or materially modifies an existing collaboration agreement, the Company will be required to apply the new multiple element guidance. Milestone payments are recognized as revenue upon achievement of pre-defined scientific events, which require substantive effort, and for which achievement of the milestone was not readily assured at the inception of the agreement.

Abbott International Luxembourg S.à r.l. In June 2010, the Company announced an exclusive worldwide collaboration with Abbott to develop and commercialize elagolix and all next-generation gonadotropin-releasing hormone (GnRH) antagonists (collectively, GnRH Compounds) for women’s and men’s health. Under the terms of the Company’s agreement with Abbott, the Company and Abbott will work jointly to advance GnRH Compounds towards commercialization. Abbott made an upfront payment of $75 million and agreed to make additional development and regulatory event based payments of up to $480 million and up to an additional $50 million in commercial event based payments. The Company has assessed event based payments under the revised authoritative guidance for research and development milestones and determined that event based payments prior to commencement of a Phase III clinical study, as defined in the agreement, meet the definition of a milestone in accordance with authoritative guidance as (1) they are events that can only be achieved in part on the Company’s past performance, (2) there is substantive uncertainty at the date the arrangement was entered into that the event will be achieved and (3) they result in additional payments being due to the Company. Development and regulatory event based payments subsequent to the commencement of a Phase III clinical study, however, currently do not meet these criteria as their achievement is based on the performance of Abbott. As of September 30, 2012, there are no further event based payments that meet the definition of a milestone in accordance with authoritative guidance.

Under the terms of the agreement, Abbott is responsible for all third-party development, marketing and commercialization costs. The Company will receive funding for certain internal collaboration expenses which includes reimbursement from Abbott for internal and external expenses related to the GnRH Compounds, which reimbursement includes up to approximately $24 million in personnel funding through the end of 2012. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. Under the terms of the Company’s agreement with Abbott, the collaboration effort between the parties to advance GnRH Compounds towards commercialization is governed by a joint development committee with representatives from both the Company and Abbott; provided, however, that final decision making authority rests with Abbott. Abbott may terminate the collaboration at its discretion upon 180 days’ written notice to the Company. In such event, the Company would be entitled to specified payments for ongoing clinical development and related activities and all GnRH Compound product rights would revert to the Company. The Company’s participation in the joint development committee has been determined to be a substantive deliverable under the contract, and therefore, the upfront payment has been deferred and is being recognized over the estimated term of the joint development committee, which is expected to be through the end of 2012. During the three and nine months ended September 30, 2012 and 2011, revenues recognized under the collaboration agreement with Abbott were as follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Milestones and amortization of up-front license fees	$	7.3	$	37.3	$	21.8	$	51.8
Sponsored research and development		1.4		2.1		4.0		7.5

Revenues recognized under the Abbott collaboration agreement	$	8.7	$	39.4	$	25.8	$	59.3

In addition, at September 30, 2012, the Company had $7.3 million of deferred revenue related to the Abbott agreement, which is being amortized over the remaining collaborative development period.

Boehringer Ingelheim International GmbH. In June 2010, the Company announced a worldwide collaboration with Boehringer Ingelheim International GmbH (Boehringer Ingelheim) to research, develop and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. Under the terms of the Company’s agreement with Boehringer Ingelheim, the Company and Boehringer Ingelheim worked jointly, during a two year collaborative research period which ended in June 2012, to identify and advance GPR119 agonist candidates into preclinical development. Following the collaborative research period, Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products, if any. The Company received a $10 million upfront payment, and received research funding to support discovery efforts. Boehringer Ingelheim agreed to make payments of up to approximately $3 million in additional preclinical milestone payments and payments of up to approximately $223 million in clinical development and commercial event based payments. The Company has assessed milestones under the revised authoritative guidance for research and development milestones and determined that the preclinical milestone payments, as defined in the agreement, meet the definition of a milestone as (1) they are events that can only be achieved in part on the Company’s performance or upon the occurrence of a specific outcome resulting from the Company’s performance, (2) there is substantive uncertainty at the date the arrangement was entered into that the event will be achieved and (3) they result in additional payments being due to the Company. Clinical development and commercial milestone payments, however, currently do not meet these criteria as their achievement is solely based on the performance of Boehringer Ingelheim. No milestone payments were recognized during the periods presented. The Company will be entitled to a percentage of any future worldwide sales of GPR119 agonists. Under the terms of the agreement, the collaboration effort between the parties to identify and advance GPR119 agonist candidates into preclinical development was initially governed by a steering committee with representatives from both the Company and Boehringer Ingelheim; provided, however, that final decision making authority rests with Boehringer Ingelheim. The Company’s participation in the steering committee was determined to be a substantive deliverable under the contract, and therefore, the upfront payment was deferred and recognized over the two-year term of the steering committee which was completed in June 2012. Boehringer Ingelheim may terminate the agreement at its discretion upon prior written notice to the Company. In such event, the Company may be entitled to specified payments and product rights would revert to the Company.

During the three and nine months ended September 30, 2012 and 2011, revenues recognized under the collaboration agreement with Boehringer Ingelheim were as follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Amortization of up-front license fees	$	—	$	1.3	$	2.2	$	3.8
Sponsored research and development		—		0.2		1.0		1.0

Revenues recognized under the Boehringer Ingelheim collaboration agreement	$	—	$	1.5	$	3.2	$	4.8

INVESTMENTS

9 Months Ended

Sep. 30, 2012

INVESTMENTS

3. INVESTMENTS

Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in comprehensive (loss) income. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.

Investments consist of the following (in thousands):


	September 30, 2012		December 31, 2011
Certificates of deposit	$	11,953	$	4,552
Commercial paper		6,982		12,467
Corporate debt securities		119,403		61,977

Total investments	$	138,338	$	78,996

The following is a summary of investments classified as available-for-sale securities (in thousands):


	Contractual Maturity (in years)	Amortized Cost		Gross Unrealized Gains(1)		Gross Unrealized Losses(1)			Aggregate Estimated Fair Value
September 30, 2012:
Classified as current assets:
Certificates of deposit	Less than 1	$	11,720	$	—	$	(6	)	$	11,714
Commercial paper	Less than 1		6,987		—		(5	)		6,982
Corporate debt securities	Less than 1		110,768		25		(16	)		110,777

Total short-term available for sale securities		$	129,475	$	25	$	(27	)	$	129,473
Classified as long-term assets:
Certificates of deposit	1-2		240		—		(1	)		239
Corporate debt securities	1-2		8,604		22		—			8,626

Total long-term available for sale securities			8,844		22		(1	)		8,865

Total available-for-sale securities		$	138,319	$	47	$	(28	)	$	138,338

December 31, 2011:
Classified as current assets:
Certificates of deposit	Less than 1	$	4,560	$	—	$	(8	)	$	4,552
Commercial paper	Less than 1		12,476		2		(11	)		12,467
Corporate debt securities	Less than 1		62,047		6		(76	)		61,977

Total short-term available-for-sale securities(2)		$	79,083	$	8	$	(95	)	$	78,996

(1)	Unrealized gains and losses are included in other comprehensive (loss) income.

(2)	The Company did not hold any long-term available-for-sale securities at December 31, 2011.

The following table presents information about available-for-sale investments in an unrealized loss position (in thousands):


	Less Than 12 Months					12 Months or Greater				Total
	Estimated Fair Value		Unrealized Losses			Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses
September 30, 2012:
Certificates of deposit	$	9,073	$	(7	)	$	—	$	—	$	9,073	$	(7	)
Commercial paper		6,982		(5	)		—		—		6,982		(5	)
Corporate debt securities		73,523		(16	)		—		—		73,523		(16	)

Total	$	89,578	$	(28	)	$	—	$	—	$	89,578	$	(28	)

December 31, 2011:
Certificates of deposit	$	4,312	$	(8	)	$	—	$	—	$	4,312	$	(8	)
Commercial paper		5,980		(11	)		—		—		5,980		(11	)
Corporate debt securities		54,974		(76	)		—		—		54,974		(76	)

Total	$	65,266	$	(95	)	$	—	$	—	$	65,266	$	(95	)

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2012

FAIR VALUE MEASUREMENTS

4. FAIR VALUE MEASUREMENTS

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:


Level 1:		Observable inputs such as quoted prices in active markets;

Level 2:		Inputs include quoted prices for similar instruments in active markets and/or quoted prices for identical or similar instruments in markets that are not active near the measurement date; and

Level 3:		Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company classifies its cash equivalents and available for sale investments within Level 1 or Level 2. The fair value of the Company’s high quality investment grade corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not reclassify any investments between levels in the fair value hierarchy during the three or nine months ended September 30, 2012.

The Company’s assets which are measured at fair value on a recurring basis as of September 30, 2012 and December 31, 2011 were determined using the inputs described above (in millions):


				Fair Value Measurements Using
	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
September 30, 2012:
Classified as current assets:
Cash and money market funds	$	43.5		$	43.5		$	—		$	—
Certificates of deposit		16.0			16.0			—			—
Commercial paper		7.0			—			7.0			—
Corporate bonds		111.8			—			111.8			—

Total		178.3			59.5			118.8			—
Less cash, cash equivalents and restricted cash		(48.8	)		(48.8	)		—			—

Total short-term investments		129.5			10.7			118.8			—
Classified as non-current assets:
Certificates of deposit		0.3			0.3			—			—
Corporate bonds		8.6			—			8.6			—

Total long-term investments	$	8.9		$	0.3		$	8.6		$	—

December 31, 2011:
Classified as current assets:
Cash and money market funds	$	50.5		$	50.5		$	—		$	—
Certificates of deposit		5.2			5.2			—			—
Commercial paper		12.5			—			12.5			—
Corporate bonds		65.2			—			65.2			—

Total		133.4			55.7			77.7			—
Less cash, cash equivalents and restricted cash		(54.4	)		(51.1	)		(3.3	)		—

Total investments(1)	$	79.0		$	4.6		$	74.4		$	—

(1)	The Company did not hold any long-term available-for-sale securities at December 31, 2011.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SHARE-BASED COMPENSATION

9 Months Ended

Sep. 30, 2012

SHARE-BASED COMPENSATION

5. SHARE-BASED COMPENSATION

As of September 30, 2012, total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $11.2 million, which is expected to be recognized over a weighted average period of approximately three years. The compensation expense related to the Company’s share-based compensation arrangements has been included in the condensed consolidated statements of comprehensive (loss) income as follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
General and administrative	$	0.7	$	0.7	$	2.1	$	1.3
Research and development		0.7		0.2	$	2.1	$	0.7

Total share-based compensation expense	$	1.4	$	0.9	$	4.2	$	2.0

During the nine months ended September 30, 2012 and 2011, stock options for approximately 140,000 and 85,000 shares of the Company’s common stock were exercised, respectively. The cash received by the Company from stock option exercises during the nine months ended September 30, 2012 and 2011 was approximately $0.4 million and $0.3 million, respectively. The Company issued approximately 50,000 and 290,000 shares of common stock pursuant to the vesting of restricted stock units (RSUs) during the nine months ended September 30, 2012 and 2011, respectively. Additionally, the Company granted 50,000 RSUs during the three and nine months ended September 30, 2011.

Stock Option Assumptions

The Company granted stock options for 1.4 million and 1.6 million shares of common stock during the nine months ended September 30, 2012 and 2011, respectively. The exercise price of all stock options granted during the nine months ended September 30, 2012 and 2011 was equal to the closing price of the Company’s common stock on the date of grant. The estimated fair value of each stock option granted was determined on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the stock option grants during the three and nine months ended September 30, 2012 and 2011:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2012	2011	2012	2011
Risk-free interest rate	0.9%	1.4%	1.3%	1.4%
Expected volatility of common stock	72.09%	81.8%	79.4%	82.1%
Dividend yield	0.0%	0.0%	0.0%	0.0%
Expected option term	6 years	6.3 years	6.8 years	6.2 years

The Company estimates the fair value of stock options using a Black-Scholes option-pricing model on the date of grant. The fair value of equity instruments that are ultimately expected to vest, net of estimated forfeitures, are recognized and amortized on a straight-line basis over the requisite service period. The Company estimates forfeiture rates for stock options based on past behavior for similar equity awards with further consideration given to the class of employees to whom the equity awards were granted. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, expected term and interest rates. The expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options. The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. Additionally, recent grants of stock options have a contractual life of ten years, versus seven years for older option grants, and the vesting period for recent option grants has been extended to four years, which together have also resulted in an increase in the expected option term. The risk-free rate for periods within the contractual life of the option is based upon observed interest rates appropriate for the expected term of the Company’s employee stock options. The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2012

STOCKHOLDERS' EQUITY

6. STOCKHOLDERS’ EQUITY

Common Stock Issuances

In January 2012, the Company completed a public offering of common stock in which the Company sold 10.9 million shares of its common stock at an offering price of $8.10 per share. The shares were sold pursuant to the Company’s effective shelf registration statement with the SEC. The net proceeds generated from this transaction, after underwriting discounts and commissions and offering costs, were approximately $83.0 million.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

REAL ESTATE

9 Months Ended

Sep. 30, 2012

REAL ESTATE

7. REAL ESTATE

In December 2007, the Company closed the sale of its facility and associated real property for a purchase price of $109 million. Concurrent with the sale, the Company retired the entire $47.7 million in mortgage debt previously outstanding with respect to the facility and associated real property, and received cash of $61.0 million net of transaction costs and debt retirement.

Upon the closing of the sale of the facility and associated real property, the Company entered into a lease agreement (Lease) with DMH Campus Investors, LLC (DMH) whereby the Company leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building.

The ultimate result of this real estate sale was a net gain of $39.1 million which was deferred in accordance with authoritative guidance in 2008. The Company recognized $0.8 million and $0.7 million of the deferred gain during the three months ended September 30, 2012 and 2011, respectively. The Company recognized $2.3 million and $2.2 million of the deferred gain during the nine months ended September 30, 2012 and 2011, respectively, and will recognize the remaining $24.8 million of the deferred gain over the initial term of the Lease which will expire at the end of 2019.

Under the terms of the Lease and the Amendments, the Company pays base annual rent (subject to an annual fixed percentage increase), plus a 3.5% annual management fee, property taxes and other normal and necessary expenses associated with the Lease such as utilities, repairs and maintenance. In lieu of a cash security deposit under the Lease, Wells Fargo Bank, N.A. has issued on the Company’s behalf a letter of credit in the amount of $4.2 million, which is secured by a deposit of equal amount with the same bank. The Company also has the right to extend the Lease for two consecutive ten-year terms.

In December 2010, the Company entered into a sublease agreement (Sublease) for approximately 16,000 square feet of the Rear Building. The Sublease is expected to result in approximately $0.6 million of rental income per year over the three year term of the Sublease and is recorded as an offset to rent expense. The Sublease provides an option to extend for two one-year renewal periods. The income generated under the Sublease is lower than the Company’s financial obligation under the Lease for the Rear Building with DMH, as determined on a per square foot basis. Consequently, at December 31, 2010 the Company was required to record a cease use liability for the net present value estimated difference between the expected income to be generated under the Sublease and future subleases and the Lease obligation over the remaining term of the Lease for the space that is occupied by the subtenant. This transaction resulted in $2.5 million of gross cease use expense, and a reversal of associated deferred rent of $173,000, being recorded in December 2010. In August 2012, the Company extended the terms of the Sublease and increased the leased square footage to approximately 17,000 square feet. This transaction resulted in approximately $150,000 of gross cease-use expense, and a reversal of associated deferred rent of $15,000, being recorded in September 2012.

In September 2011, the Company entered into a second sublease agreement (Second Sublease) for approximately 3,300 square feet of space in the Rear Building. The Second Sublease is expected to result in approximately $0.1 million in rental income per year over the three year term and is recorded as an offset to rent expense. The Second Sublease provides an option to extend for a one-year renewal period. Similar to the Sublease, this Second Sublease resulted in $0.3 million of gross cease use expense, and a reversal of associated deferred rent of $47,000, being recorded in September 2011.

At September 30, 2012 and 2011, the Company had recorded in its consolidated balance sheet a cease-use liability related to both the Sublease (as amended) and the Second Sublease of $2.5 million and $2.6 million, respectively. At September 30, 2011, the Company also had a liability of $4.3 million to the landlord related to the Amendments which permitted the Company to vacate the Front Building. This liability was retired in its entirety during 2011.

The following table sets forth changes to the accrued cease-use liability during the three and nine months ended September 30, 2012 and 2011 (in thousands):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Beginning balance	$	2,463		$	7,708		$	2,592		$	9,965
Accrued cease use costs		—			63			—			239
Impact of Sublease cease-use charges (1)		150			324			150			324
Change in estimate		—			(427	)		—			(427	)
Payments		(64	)		(729	)		(193	)		(3,162	)

Ending balance	$	2,549		$	6,939		$	2,549		$	6,939

(1)	Total cease-use expense was offset by the related adjustment to deferred rent of approximately $15,000 during 2012 and $47,000 during 2011.

(LOSS) INCOME PER COMMON SHARE

9 Months Ended

Sep. 30, 2012

(LOSS) INCOME PER COMMON SHARE

8. (LOSS) INCOME PER COMMON SHARE

The Company computes basic net (loss) income per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Additionally, potentially dilutive securities, composed of incremental common shares issuable upon the exercise of stock options and warrants and the vesting of RSUs, are excluded from the diluted loss per share calculation because of their anti-dilutive effect.

For the three and nine months ended September 30, 2012, the Company realized a net loss of $3.1 million and $4.5 million, respectively. Potentially dilutive securities, composed of incremental common shares issuable upon the exercise of stock options and warrants and the vesting of RSUs, are excluded from the historical diluted loss per share because of their anti-dilutive effect. Potentially dilutive securities excluded from the historical diluted loss per share totaled approximately 1.3 million for each of the three and nine months ended September 30, 2012. Options to purchase approximately 2.3 million shares of common stock were outstanding during the nine months ended September 30, 2012 with an exercise price greater than the average market price of the underlying common shares.

For the three and nine months ended September 30, 2011, the Company realized net income of $31.4 million and $36.2 million, respectively. This resulted in the addition of approximately 1.1 million of potentially dilutive securities, consisting of employee equity awards, to the total diluted shares outstanding used in the calculation of net income per common share for each of the three and nine months ended September 30, 2011. In addition, options to purchase approximately 1.4 million shares of common stock were outstanding during each of the three and nine months ended September 30, 2011, but were not included in the computation of diluted earnings per share as such options had an exercise price that was greater than the average market price of the underlying common shares.

RESEARCH AND DEVELOPMENT

9 Months Ended

Sep. 30, 2012

RESEARCH AND DEVELOPMENT

9. RESEARCH AND DEVELOPMENT

Research and development (R&D) expenses consists primarily of salaries, payroll taxes, employee benefits, and share-based compensation charges, for those individuals involved in ongoing R&D efforts; as well as scientific contractor fees, preclinical and clinical trial costs, R&D facilities costs, laboratory supply costs, and depreciation of scientific equipment. All such costs are charged to R&D expense as incurred. These expenses result from the Company’s independent R&D efforts as well as efforts associated with collaborations and in-licensing arrangements. In addition, the Company funds R&D at other companies and research institutions under agreements, which are generally cancelable. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.

INCOME TAXES

9 Months Ended

Sep. 30, 2012

INCOME TAXES

10. INCOME TAXES

In January 2007, the Company adopted the provisions of the FASB’s authoritative accounting guidance, which, among other things, related to uncertain tax provisions. Under the accounting guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. There were no unrecognized tax benefits as of the date of adoption. As a result of the implementation of the guidance, the Company did not recognize an increase in the liability for unrecognized tax benefits. There were no unrecognized tax benefits included in the Company’s condensed consolidated balance sheet as of September 30, 2012 that would, if recognized, affect the Company’s effective tax rate.

The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheets at December 31, 2011 or at September 30, 2012, and has not recognized interest and/or penalties in the condensed consolidated statement of comprehensive (loss) income for the first nine months of 2012.

The Company is subject to taxation in the United States and various state jurisdictions. The Company’s tax years for 1995 and forward are subject to examination by the United States and California tax authorities due to the carryforward of unutilized net operating losses and R&D credits.

At December 31, 2011, the Company had net deferred tax assets of $325.3 million. Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these assets, a full valuation has been established to offset the net deferred tax asset. Additionally, the future utilization of the Company’s net operating loss and research and development credit carry forwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. The Company has determined that no ownership changes have occurred through December 31, 2011. As a result of this analysis, the Company has re-established its deferred tax assets for net operating losses of $238.0 million and research and development credits of $26.3 million through 2011, with a corresponding increase to its valuation allowance. Due to the existence of the valuation allowance, future changes in the Company’s unrecognized tax benefits will not impact the Company’s effective tax rate.

At December 31, 2011, the Company had Federal and California income tax net operating loss carry forwards of approximately $602.2 million and $598.8 million, respectively. The Federal and California tax loss carry forwards will begin to expire in 2015 and 2016, respectively, unless previously utilized. In addition, the Company had Federal and California research and development tax credit carry forwards of $30.2 million and $20.8 million, respectively. The Federal research and development tax credit carry forwards began expiring in 2007 and will continue to expire unless utilized. There were $842,000 of Federal research and development tax credit carryforwards that have expired through 2011. The California research and development tax credit carryforwards carry forward indefinitely. The Company also had Federal Alternative Minimum Tax credit carryforwards of approximately $257,000, which will carry forward indefinitely. At December 31, 2011, approximately $17.5 million of the net operating loss carry forwards related to stock option exercises, which will result in an increase to additional paid-in capital and a decrease in income taxes payable at the time when the tax loss carryforwards are utilized. As of December 31, 2011, the Company had $17.4 million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2012
SUBSEQUENT EVENTS	11. SUBSEQUENT EVENTS The Company has evaluated all subsequent events that have occurred after the date of the accompanying financial statements and determined that there were no events or transactions occurring during this subsequent event reporting period which require recognition or disclosure in the Company’s financial statements.

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2012
Basis of Presentation	Basis of Presentation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2011 included in the Company’s Annual Report on Form 10-K filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2011 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
Impact of Recently Issued Accounting Standards	Impact of Recently Issued Accounting Standards. In December 2011, the Financial Accounting Standards Board (FASB) issued accounting guidance requiring an entity to disclose information about offsetting arrangements and the impact of these arrangements on the Company’s financial position. This guidance is effective for interim and annual periods beginning on or after January 1, 2013. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements. In May 2011, the FASB issued updated accounting guidance that clarifies existing fair value measurements and disclosures, and eliminates differences between GAAP and International Financial Reporting Standards to make convergence guidance more understandable. This guidance is effective for interim and annual periods beginning after December 15, 2011. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. Effective January 1, 2012, the Company adopted guidance issued by the FASB concerning presentation and disclosure only for the presentation of comprehensive (loss) income. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial position or results of operations, other than its impact on the presentation of comprehensive (loss) income.
Use of Estimates	Use of Estimates. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS (Tables)

9 Months Ended

Sep. 30, 2012

Abbott International Luxembourg S.a.r.l.

Revenues Recognized under Collaboration Agreements

During the three and nine months ended September 30, 2012 and 2011, revenues recognized under the collaboration agreement with Abbott were as follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Milestones and amortization of up-front license fees	$	7.3	$	37.3	$	21.8	$	51.8
Sponsored research and development		1.4		2.1		4.0		7.5

Revenues recognized under the Abbott collaboration agreement	$	8.7	$	39.4	$	25.8	$	59.3

Boehringer Ingelheim

Revenues Recognized under Collaboration Agreements

During the three and nine months ended September 30, 2012 and 2011, revenues recognized under the collaboration agreement with Boehringer Ingelheim were as follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Amortization of up-front license fees	$	—	$	1.3	$	2.2	$	3.8
Sponsored research and development		—		0.2		1.0		1.0

Revenues recognized under the Boehringer Ingelheim collaboration agreement	$	—	$	1.5	$	3.2	$	4.8

INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2012

Investments

Investments consist of the following (in thousands):


	September 30, 2012		December 31, 2011
Certificates of deposit	$	11,953	$	4,552
Commercial paper		6,982		12,467
Corporate debt securities		119,403		61,977

Total investments	$	138,338	$	78,996

Summary of Investments Classified as Available-For-Sale Securities

The following is a summary of investments classified as available-for-sale securities (in thousands):


	Contractual Maturity (in years)	Amortized Cost		Gross Unrealized Gains(1)		Gross Unrealized Losses(1)			Aggregate Estimated Fair Value
September 30, 2012:
Classified as current assets:
Certificates of deposit	Less than 1	$	11,720	$	—	$	(6	)	$	11,714
Commercial paper	Less than 1		6,987		—		(5	)		6,982
Corporate debt securities	Less than 1		110,768		25		(16	)		110,777

Total short-term available for sale securities		$	129,475	$	25	$	(27	)	$	129,473
Classified as long-term assets:
Certificates of deposit	1-2		240		—		(1	)		239
Corporate debt securities	1-2		8,604		22		—			8,626

Total long-term available for sale securities			8,844		22		(1	)		8,865

Total available-for-sale securities		$	138,319	$	47	$	(28	)	$	138,338

December 31, 2011:
Classified as current assets:
Certificates of deposit	Less than 1	$	4,560	$	—	$	(8	)	$	4,552
Commercial paper	Less than 1		12,476		2		(11	)		12,467
Corporate debt securities	Less than 1		62,047		6		(76	)		61,977

Total short-term available-for-sale securities(2)		$	79,083	$	8	$	(95	)	$	78,996

(1)	Unrealized gains and losses are included in other comprehensive (loss) income.

(2)	The Company did not hold any long-term available-for-sale securities at December 31, 2011.

Available-For-Sale Investments in Unrealized Loss Position

The following table presents information about available-for-sale investments in an unrealized loss position (in thousands):


	Less Than 12 Months					12 Months or Greater				Total
	Estimated Fair Value		Unrealized Losses			Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses
September 30, 2012:
Certificates of deposit	$	9,073	$	(7	)	$	—	$	—	$	9,073	$	(7	)
Commercial paper		6,982		(5	)		—		—		6,982		(5	)
Corporate debt securities		73,523		(16	)		—		—		73,523		(16	)

Total	$	89,578	$	(28	)	$	—	$	—	$	89,578	$	(28	)

December 31, 2011:
Certificates of deposit	$	4,312	$	(8	)	$	—	$	—	$	4,312	$	(8	)
Commercial paper		5,980		(11	)		—		—		5,980		(11	)
Corporate debt securities		54,974		(76	)		—		—		54,974		(76	)

Total	$	65,266	$	(95	)	$	—	$	—	$	65,266	$	(95	)

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2012

Assets Measured at Fair Value on Recurring Basis

The Company’s assets which are measured at fair value on a recurring basis as of September 30, 2012 and December 31, 2011 were determined using the inputs described above (in millions):


				Fair Value Measurements Using
	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
September 30, 2012:
Classified as current assets:
Cash and money market funds	$	43.5		$	43.5		$	—		$	—
Certificates of deposit		16.0			16.0			—			—
Commercial paper		7.0			—			7.0			—
Corporate bonds		111.8			—			111.8			—

Total		178.3			59.5			118.8			—
Less cash, cash equivalents and restricted cash		(48.8	)		(48.8	)		—			—

Total short-term investments		129.5			10.7			118.8			—
Classified as non-current assets:
Certificates of deposit		0.3			0.3			—			—
Corporate bonds		8.6			—			8.6			—

Total long-term investments	$	8.9		$	0.3		$	8.6		$	—

December 31, 2011:
Classified as current assets:
Cash and money market funds	$	50.5		$	50.5		$	—		$	—
Certificates of deposit		5.2			5.2			—			—
Commercial paper		12.5			—			12.5			—
Corporate bonds		65.2			—			65.2			—

Total		133.4			55.7			77.7			—
Less cash, cash equivalents and restricted cash		(54.4	)		(51.1	)		(3.3	)		—

Total investments(1)	$	79.0		$	4.6		$	74.4		$	—

(1)	The Company did not hold any long-term available-for-sale securities at December 31, 2011.

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References + Details

SHARE-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2012

Compensation Expense Related to Share-Based Compensation

The compensation expense related to the Company’s share-based compensation arrangements has been included in the condensed consolidated statements of comprehensive (loss) income as follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
General and administrative	$	0.7	$	0.7	$	2.1	$	1.3
Research and development		0.7		0.2	$	2.1	$	0.7

Total share-based compensation expense	$	1.4	$	0.9	$	4.2	$	2.0

Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model

The estimated fair value of each stock option granted was determined on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the stock option grants during the three and nine months ended September 30, 2012 and 2011:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2012	2011	2012	2011
Risk-free interest rate	0.9%	1.4%	1.3%	1.4%
Expected volatility of common stock	72.09%	81.8%	79.4%	82.1%
Dividend yield	0.0%	0.0%	0.0%	0.0%
Expected option term	6 years	6.3 years	6.8 years	6.2 years

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

REAL ESTATE (Tables)

9 Months Ended

Sep. 30, 2012

Changes to Accrued Cease-Use Liability

The following table sets forth changes to the accrued cease-use liability during the three and nine months ended September 30, 2012 and 2011 (in thousands):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Beginning balance	$	2,463		$	7,708		$	2,592		$	9,965
Accrued cease use costs		—			63			—			239
Impact of Sublease cease-use charges (1)		150			324			150			324
Change in estimate		—			(427	)		—			(427	)
Payments		(64	)		(729	)		(193	)		(3,162	)

Ending balance	$	2,549		$	6,939		$	2,549		$	6,939

(1)	Total cease-use expense was offset by the related adjustment to deferred rent of approximately $15,000 during 2012 and $47,000 during 2011.

Organization and Significant Accounting Policies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2012
Entity First Incorporation
Organization And Summary Of Significant Accounting Policies [Line Items]
Date of incorporation	1992
Place of incorporation	California
Entity Second Incorporation
Organization And Summary Of Significant Accounting Policies [Line Items]
Date of incorporation	1996
Place of incorporation	Delaware

Revenue Recognition and Significant Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended
	Jun. 30, 2010	Sep. 30, 2012
Abbott International Luxembourg S.a.r.l.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement upfront payment received	$ 75.0
Collaborative arrangement right description	The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.
Patent rights period	10 years
Collaboration termination notice period	180 days
Deferred revenue related to collaborative agreement		$ 7.3
Abbott International Luxembourg S.a.r.l. \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Reimbursement in personnel funding	$ 24.0
Abbott International Luxembourg S.a.r.l. \| Development and regulatory event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	480.0
Abbott International Luxembourg S.a.r.l. \| Commercial event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	50.0
Boehringer Ingelheim
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement upfront payment received	$ 10.0
Collaborative research period	2 years
Deferred upfront payment recognition period	2 years
Boehringer Ingelheim \| Preclinical milestone payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	$ 3.0
Boehringer Ingelheim \| Clinical development and commercial event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	$ 223.0

Revenues Recognized under Collaboration Agreement with Abbott (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sponsored research and development	$ 1,369	$ 2,396	$ 4,938	$ 8,589
Abbott International Luxembourg S.a.r.l.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amortization of up-front license fees	7,300	37,300	21,800	51,800
Sponsored research and development	1,400	2,100	4,000	7,500
Revenues recognized under collaboration agreement	$ 8,700	$ 39,400	$ 25,800	$ 59,300

Revenues Recognized under Collaboration Agreement with Boehringer Ingelheim (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sponsored research and development	$ 1,369	$ 2,396	$ 4,938	$ 8,589
Boehringer Ingelheim
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amortization of up-front license fees		1,300	2,200	3,800
Sponsored research and development		200	1,000	1,000
Revenues recognized under collaboration agreement		$ 1,500	$ 3,200	$ 4,800

Investments (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Schedule of Investments [Line Items]
Investments	$ 138,338	$ 78,996
Certificates of deposit
Schedule of Investments [Line Items]
Investments	11,953	4,552
Commercial paper
Schedule of Investments [Line Items]
Investments	6,982	12,467
Corporate debt securities
Schedule of Investments [Line Items]
Investments	$ 119,403	$ 61,977

- Definition

Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=7534914&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15C
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15E
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Summary of Investments Classified as Available-For-Sale Securities (Detail) - USD ($)
$ in Thousands

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

$ 138,319

Gross Unrealized Gains

^[1]

Gross Unrealized Losses

^[1]

(28)

Aggregate Estimated Fair Value

138,338

Short-term investments

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

129,475

$ 79,083

^[2]

Gross Unrealized Gains

^[1]

^[2]

Gross Unrealized Losses

^[1]

(27)

(95)

^[2]

Aggregate Estimated Fair Value

129,473

78,996

^[2]

Short-term investments | Certificates of deposit

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

11,720

4,560

Gross Unrealized Losses

^[1]

(6)

(8)

Aggregate Estimated Fair Value

$ 11,714

$ 4,552

Short-term investments | Certificates of deposit | Maximum

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

1 year

Short-term investments | Commercial paper

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

$ 6,987

$ 12,476

Gross Unrealized Gains

^[1]

Gross Unrealized Losses

^[1]

(5)

(11)

Aggregate Estimated Fair Value

$ 6,982

$ 12,467

Short-term investments | Commercial paper | Maximum

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

1 year

Short-term investments | Corporate debt securities

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

$ 110,768

$ 62,047

Gross Unrealized Gains

^[1]

Gross Unrealized Losses

^[1]

(16)

(76)

Aggregate Estimated Fair Value

$ 110,777

$ 61,977

Short-term investments | Corporate debt securities | Maximum

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

1 year

Long-term investments

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

$ 8,844

Gross Unrealized Gains

^[1]

Gross Unrealized Losses

^[1]

(1)

Aggregate Estimated Fair Value

8,865

Long-term investments | Certificates of deposit

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

240

Gross Unrealized Losses

^[1]

(1)

Aggregate Estimated Fair Value

$ 239

Long-term investments | Certificates of deposit | Minimum

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

1 year

Long-term investments | Certificates of deposit | Maximum

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

2 years

Long-term investments | Corporate debt securities

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost

$ 8,604

Gross Unrealized Gains

^[1]

Aggregate Estimated Fair Value

$ 8,626

Long-term investments | Corporate debt securities | Minimum

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

1 year

Long-term investments | Corporate debt securities | Maximum

Schedule of Available-for-sale Securities [Line Items]

Available for sale securities contractual maturity

2 years

[1]	Unrealized gains and losses are included in other comprehensive (loss) income.
[2]	The Company did not hold any long-term available-for-sale securities at December 31, 2011.

Available-For-Sale Investments in Unrealized Loss Position (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Investments, Unrealized Loss Position [Line Items]
Less Than 12 Months, Estimated Fair Value	$ 89,578	$ 65,266
Less Than 12 Months, Unrealized Losses	(28)	(95)
12 Month or Greater, Estimated Fair Value
12 Month or Greater, Unrealized Losses
Total Estimated Fair Value	89,578	65,266
Total Unrealized Losses	(28)	(95)
Certificates of deposit
Investments, Unrealized Loss Position [Line Items]
Less Than 12 Months, Estimated Fair Value	9,073	4,312
Less Than 12 Months, Unrealized Losses	(7)	(8)
12 Month or Greater, Estimated Fair Value
12 Month or Greater, Unrealized Losses
Total Estimated Fair Value	9,073	4,312
Total Unrealized Losses	(7)	(8)
Commercial paper
Investments, Unrealized Loss Position [Line Items]
Less Than 12 Months, Estimated Fair Value	6,982	5,980
Less Than 12 Months, Unrealized Losses	(5)	(11)
12 Month or Greater, Estimated Fair Value
12 Month or Greater, Unrealized Losses
Total Estimated Fair Value	6,982	5,980
Total Unrealized Losses	(5)	(11)
Corporate debt securities
Investments, Unrealized Loss Position [Line Items]
Less Than 12 Months, Estimated Fair Value	73,523	54,974
Less Than 12 Months, Unrealized Losses	(16)	(76)
12 Month or Greater, Estimated Fair Value
12 Month or Greater, Unrealized Losses
Total Estimated Fair Value	73,523	54,974
Total Unrealized Losses	$ (16)	$ (76)

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Unrecognized compensation cost		$ 11.2
Unrecognized compensation cost, weighted average period of recognition		3 years
Stock option exercised		140,000	85,000
Cash received from stock option exercises		$ 0.4	$ 0.3
Common stock issued pursuant to the vesting of restricted stock units (RSUs)		50,000	290,000
Stock options granted		1,400,000	1,600,000
Stock option contractual life		10 years
Stock option vesting period		4 years
Restricted Stock Units (RSUs)
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Additional restricted stock units (RSUs) granted	50,000		50,000
Scenario, Previously Reported
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Stock option contractual life		7 years

Compensation Expense Related to Share-Based Compensation (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Total share-based compensation expense	$ 1.4	$ 0.9	$ 4.2	$ 2.0
General and Administrative Expense
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Total share-based compensation expense	0.7	0.7	2.1	1.3
Research and Development Expense
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Total share-based compensation expense	$ 0.7	$ 0.2	$ 2.1	$ 0.7

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References + Details

Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Detail) - Stock Option	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Schedule of Weighted Average Assumptions for Fair Values of Stock Options[Line Items]
Risk-free interest rate	0.90%	1.40%	1.30%	1.40%
Expected volatility of common stock	72.09%	81.80%	79.40%	82.10%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected option term	6 years	6 years 3 months 18 days	6 years 9 months 18 days	6 years 2 months 12 days

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended	9 Months Ended
	Jan. 31, 2012	Sep. 30, 2012	Sep. 30, 2011
Stockholders Equity Note [Line Items]
Common stock issued	10.9
Common stock, offering price	$ 8.10
Proceeds from common stock issuance	$ 83,000	$ 83,414	$ 264

Real Estate - Additional Information (Detail)

1 Months Ended

3 Months Ended

9 Months Ended

Aug. 31, 2012

ft²

Sep. 30, 2011

USD ($)

ft²

Dec. 31, 2010

USD ($)

ft²

Dec. 31, 2007

USD ($)

Entity

Sep. 30, 2012

USD ($)

Sep. 30, 2011

USD ($)

Sep. 30, 2012

USD ($)

Sep. 30, 2011

USD ($)

Jun. 30, 2012

USD ($)

Dec. 31, 2011

USD ($)

Jun. 30, 2011

USD ($)

Dec. 31, 2008

USD ($)

Real Estate Properties [Line Items]

Sale of facility and associated real property

$ 109,000,000

Mortgage debt retired

47,700,000

Cash received net of transaction costs and debt retirement

$ 61,000,000

Sale leaseback transaction term

the Company entered into a lease agreement (Lease) with DMH Campus Investors, LLC (DMH) whereby the Company leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building.

Leaseback transaction lease period

12 years

Net deferred gain on real estate sale

$ 24,800,000

$ 39,100,000

Deferred gain recognized

800,000

$ 700,000

$ 2,300,000

$ 2,200,000

Deferred gain, initial lease expiration year

2019

Subleased space (in square feet) | ft²

17,000

16,000

Sublease agreement, annual rental income

$ 600,000

Sublease term

3 years

Cease-use expense

135,000

(87,000)

$ 135,000

89,000

Cease use liability related

$ 6,939,000

$ 9,965,000

2,549,000

6,939,000

2,549,000

6,939,000

$ 2,463,000

$ 2,592,000

$ 7,708,000

Liability related to landlord

$ 4,300,000

4,300,000

Second Sublease

Real Estate Properties [Line Items]

Subleased space (in square feet) | ft²

3,300

Sublease agreement, annual rental income

$ 100,000

Sublease term

3 years

Renewal periods

1 year

Cease-use expense

$ 300,000

Deferred rent reversed

47,000

Sublease

Real Estate Properties [Line Items]

Number of times to renew the lease contract

Renewal periods

1 year

Cease-use expense

$ 2,500,000

150,000

^[1]

324,000

^[1]

150,000

^[1]

324,000

^[1]

Deferred rent reversed

$ 173,000

15,000

47,000

Cease use liability related

$ 2,600,000

$ 2,500,000

$ 2,600,000

$ 2,500,000

$ 2,600,000

Lease Back Type Transactions

Real Estate Properties [Line Items]

Number of building leased | Entity

Percentage of management fee included in the base annual rent

3.50%

Letter of credit

$ 4,200,000

Lease extension period

10 years

Number of times to renew the lease contract

[1]	Total cease-use expense was offset by the related adjustment to deferred rent of approximately $15,000 during 2012 and $47,000 during 2011.

Changes to Accrued Cease-Use Liability (Detail) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

Dec. 31, 2010

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Real Estate Properties [Line Items]

Beginning balance

$ 2,463,000

$ 7,708,000

$ 2,592,000

$ 9,965,000

Accrued cease use costs

63,000

239,000

Impact of cease-use charges

135,000

(87,000)

135,000

89,000

Change in estimate

(427,000)

Payments

(64,000)

(729,000)

(193,000)

(3,162,000)

Ending balance

$ 9,965,000

2,549,000

6,939,000

2,549,000

6,939,000

Sublease

Real Estate Properties [Line Items]

Impact of cease-use charges

$ 2,500,000

150,000

^[1]

324,000

^[1]

150,000

^[1]

324,000

^[1]

Ending balance

$ 2,500,000

$ 2,600,000

$ 2,500,000

$ 2,600,000

[1]	Total cease-use expense was offset by the related adjustment to deferred rent of approximately $15,000 during 2012 and $47,000 during 2011.

Changes to Accrued Cease-Use Liability (Parenthetical) (Detail) - USD ($)	1 Months Ended	9 Months Ended
	Dec. 31, 2010	Sep. 30, 2012	Sep. 30, 2011
Sublease
Real Estate Properties [Line Items]
Deferred rent reversed	$ 173,000	$ 15,000	$ 47,000

(Loss) Income Per Common Share - Additional Information (Detail) - USD ($) $ in Thousands, shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]
Net (loss) income	$ (3,078)	$ 31,382	$ (4,465)	$ 36,240
Potentially dilutive securities	1.3	1.1	1.3	1.1
Shares of common stock excluded from computation of diluted earnings per share outstanding		1.4	2.3	1.4

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Income Taxes - Additional Information (Detail)	1 Months Ended
Income Taxes - Additional Information (Detail)	Dec. 31, 2011 USD ($)
Income Taxes [Line Items]
Deferred tax assets, net	$ 325,300,000
Deferred tax assets for net operating losses	238,000,000
Deferred tax assets for research and development credits	26,300,000
Net operating loss carry forwards related to stock option exercises	17,500,000
Unrecognized tax benefits that would affect the effective tax rate	17,400,000
Federal
Income Taxes [Line Items]
Operating loss carry forward, net	$ 602,200,000
Operating loss carry forward beginning expiration year	2015
Research and development tax credit carry forwards	$ 30,200,000
Alternative Minimum Tax credit carry forwards	$ 257,000
Federal \| Research And Development
Income Taxes [Line Items]
Tax credit carry forwards beginning expiration year	2007
Tax credit carry forwards amount expired through 2011	$ 842,000
California
Income Taxes [Line Items]
Operating loss carry forward, net	$ 598,800,000
Operating loss carry forward beginning expiration year	2016
Research and development tax credit carry forwards	$ 20,800,000